Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 9,459 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.23, for a total transaction of $872,403.57. Following the completion of the sale, the senior vice president owned 15,312 shares in the company, valued at approximately $1,412,225.76. This trade represents a 38.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total transaction of $53,597.60.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00.
• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total transaction of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The stock was sold at an average price of $80.95, for a total value of $128,467.65.

Oruka Therapeutics Trading Down 3.9%

ORKA stock traded down $3.73 during trading on Tuesday, hitting $92.20. The stock had a trading volume of 784,617 shares, compared to its average volume of 741,278. Oruka Therapeutics, Inc. has a twelve month low of $14.66 and a twelve month high of $115.51. The company’s 50-day moving average price is $95.87 and its two-hundred day moving average price is $72.78.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Institutional Trading of Oruka Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sei Investments Co. grew its holdings in shares of Oruka Therapeutics by 136.0% in the first quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock valued at $1,120,000 after purchasing an additional 13,164 shares during the period. Dimensional Fund Advisors LP purchased a new position in Oruka Therapeutics during the first quarter worth about $5,543,000. Handelsbanken Fonder AB purchased a new position in Oruka Therapeutics during the second quarter worth about $15,313,000. The Manufacturers Life Insurance Company boosted its holdings in Oruka Therapeutics by 18.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock valued at $3,559,000 after purchasing an additional 11,205 shares during the last quarter. Finally, BlackRock Inc. acquired a new position in Oruka Therapeutics in the 2nd quarter valued at about $474,916,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. BTIG Research restated a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Mizuho set a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday, September 3rd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $133.00.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.